LAVIPHARM S.A. Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with the intention to commercialize them internationally.
Historical total sales of both pharmaceutical products amounted to approximately €8 mio annually (Wholesale Prices). The transaction will be financed by the company's own funds. The products are commercially available in the Greek market and are expected to be marketed by Lavipharm during the first quarter of 2024 upon completion of the relevant product marketing authorizations' transfer.
It is with great enthusiasm and pride that we welcome Lonarid N® and Lonalgal® in our portfolio. Their addition strengthens our position in pain management and expands substantially the options Lavipharm offers to healthcare professionals to optimally meet patients' therapeutic needs", commented Telemaque Lavidas, Executive Board Member of Lavipharm.
With a history counting over a century, Lavipharm has been active in the pharmaceutical industry since 1911, consistently aiming at assisting healthcare professionals in their work by providing reliable therapeutic options. Its portfolio includes innovative and effective pharmaceutical products that cater for patients' daily needs.
###
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Lavipharm SA published this content on 01 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2023 08:14:17 UTC.
